Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Antti Turunen; Jaakko Valtola; Anu Partanen; Antti Ropponen; Outi Kuittinen; Hanne Kuitunen; Kaija Vasala; Lasse Ågren; Karri Penttilä; Leena Keskinen; Eeva-Riitta Savolainen; Marja Pyörälä; Taru Kuittinen; Tuomas Selander; Pentti Mäntymaa; Jukka Pelkonen; Esa Jantunen; Ville Varmavuo

doi:10.1080/10428194.2020.1762879

Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Leuk Lymphoma. 2020 Sep;61(9):2082-2092. doi: 10.1080/10428194.2020.1762879. Epub 2020 May 18.

Authors

Antti Turunen^{1

2}, Jaakko Valtola^{1

3}, Anu Partanen¹, Antti Ropponen⁴, Outi Kuittinen^{2

5

6}, Hanne Kuitunen⁶, Kaija Vasala⁷, Lasse Ågren⁸, Karri Penttilä^{3

9}, Leena Keskinen¹⁰, Eeva-Riitta Savolainen¹¹, Marja Pyörälä¹, Taru Kuittinen¹, Tuomas Selander¹², Pentti Mäntymaa¹³, Jukka Pelkonen^{4

13}, Esa Jantunen^{1

2

8}, Ville Varmavuo¹⁴

Affiliations

¹ Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
² Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
³ Department of Medicine, Savonlinna Central Hospital, Savonlinna, Finland.
⁴ Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland.
⁵ Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
⁶ Department of Oncology, Oulu University Hospital, Oulu, Finland.
⁷ Department of Oncology, Central Hospital of Central Finland, Jyväskylä, Finland.
⁸ Department of Medicine, North Carelia Hospital District, Joensuu, Finland.
⁹ Finnish Medicines Agency, Kuopio, Finland.
¹⁰ Department of Oncology, Tampere University Hospital, Tampere, Finland.
¹¹ Nordlab, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.
¹² Science Service Center, Kuopio University Hospital, Kuopio, Finland.
¹³ Laboratory Centre of Eastern Finland, Kuopio, Finland.
¹⁴ Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland.

PMID: 32419549
DOI: 10.1080/10428194.2020.1762879

Abstract

Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed in 129 NHL patients. Higher graft CD34⁺ cell content (>2.5 × 10⁶/kg) correlated with better progression-free survival (PFS) (p=.009) and overall survival (OS) (p=.004). Higher graft CD34⁺CD133⁺CD38^- counts (>0.08 × 10⁶/kg) were also linked with better PFS (p=.03) and OS (p=.004), and these survival benefits retained in multivariate analyses. Higher infused CD3⁺CD4⁺ cell count (>37 × 10⁶/kg) predicted better PFS (p=.013) and OS (p=.007) in multivariate analysis. Autograft cellular composition seems to impact outcome in NHL patients. These observations regarding composition of optimal graft in autologous setting should be validated in an independent patient series or in a randomized study.

Keywords: Non-Hodgkin lymphoma; autologous stem cell transplantation; flow cytometry; graft cellular composition; outcome.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Autografts
Disease-Free Survival
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Non-Hodgkin* / therapy
Prospective Studies
Transplantation, Autologous
Treatment Outcome